Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xia Li Qi Jiaonang (夏荔芪胶囊) is a Chinese patent medicine formulated as a hard capsule containing brown to dark brown granules. It is primarily used for the treatment of mild to moderate benign prostatic hyperplasia (BPH) in patients with spleen-kidney qi deficiency and phlegm-stasis syndrome according to traditional Chinese medicine (TCM) theory. The main ingredients include Astragalus membranaceus (Huangqi), Ligustrum lucidum (Nvzhenzi), Talcum, Prunella vulgaris (Xiakucao), Litchi seed (Lizhihe), Amber, Cinnamomum cassia (Rougui), and Phellodendron amurense (Huangbai). The mechanism of action is based on TCM principles—tonifying the spleen and kidney, promoting diuresis, resolving masses—and it has demonstrated efficacy in improving urinary symptoms such as weak urination and frequent nocturia in clinical studies. Phase II and III trials have shown statistically significant improvements over control groups in symptom scores but not in prostate volume or residual urine volume[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on xialiqi jiaonang.